• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • vagus nerve stimulation
Transcutaneous Auricular Vagus Nerve Stimulation: A Promising New Therapy for Erythematotelangiectatic Rosacea
Posted inDermatology Neurology news

Transcutaneous Auricular Vagus Nerve Stimulation: A Promising New Therapy for Erythematotelangiectatic Rosacea

Posted by By MedXY 10/08/2025
A randomized trial demonstrates that 3 weeks of transcutaneous auricular vagus nerve stimulation significantly reduces facial erythema, flushing, and associated neuropsychiatric symptoms in erythematotelangiectatic rosacea, with effects persisting 24 weeks post-treatment.
Read More
Long-Term Outcomes of Vagus Nerve Stimulation Paired With Upper Extremity Rehabilitation After Stroke
Posted inClinical Updates Neurology news Specialties

Long-Term Outcomes of Vagus Nerve Stimulation Paired With Upper Extremity Rehabilitation After Stroke

Posted by By MedXY 08/17/2025
This study evaluates the lasting benefits of vagus nerve stimulation combined with rehabilitation for stroke patients suffering from upper extremity impairments.
Read More
Enhancing Exercise Capacity Through Non-Invasive Vagus Nerve Stimulation: Evidence from a Randomized Controlled Trial
Posted inNeurology news Specialties

Enhancing Exercise Capacity Through Non-Invasive Vagus Nerve Stimulation: Evidence from a Randomized Controlled Trial

Posted by By MedXY 08/13/2025
A randomized trial demonstrates that non-invasive transcutaneous vagus nerve stimulation improves peak oxygen uptake and exercise performance in healthy volunteers, highlighting its potential as a safe and scalable method to boost cardiorespiratory fitness.
Read More
FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease
Posted inClinical Updates news Rheumatology Specialties

FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease

Posted by By MedXY 07/31/2025
The FDA has approved the first vagus nerve stimulation device for moderate-to-severe rheumatoid arthritis unresponsive to biologic or synthetic DMARDs, offering a novel neuromodulatory approach to disease management.
Read More
  • Venetoclax‑Obinutuzumab in First‑Line CLL: Efficacy Preserved in Unfit Patients — but Dose Intensity Matters
  • Long-term Outcomes in Congenital TTP: Registry Data Show Prophylactic Plasma Reduces Clinical Events but Symptoms and Product Burden Persist
  • DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results
  • DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18
  • Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial depression diabetes diet epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial screening sexual health sleep treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in